Levodopa
- Generic Name
- Levodopa
- Brand Names
- Dhivy, Duodopa, Duopa, Inbrija, Parcopa, Prolopa, Rytary, Sinemet, Stalevo
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11NO4
- CAS Number
- 59-92-7
- Unique Ingredient Identifier
- 46627O600J
- Background
Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after it has crossed the b...
- Indication
Levodopa on its own is formulated as an oral inhalation powder indicated for intermittent treatment of off episodes in Parkinson's patients who are already being treated with carbidopa and levodopa. Levodopa is most commonly formulated as an oral tablet with a peripheral dopa decarboxylase inhibitor indicated for treatment of Parkinson's disease, post-enceph...
- Associated Conditions
- Paralysis agitans, Parkinson's Disease (PD), Parkinsonism, Parkinsonism post encephalitic, Restless Legs Syndrome (RLS), Advanced Motor fluctuations
- Associated Therapies
- -
Trial of L-DOPA as a Treatment to Improve Vision in Albinism
- First Posted Date
- 2010-08-06
- Last Posted Date
- 2018-05-02
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 45
- Registration Number
- NCT01176435
- Locations
- 🇺🇸
University of Minnesota Eye Clinic, Minneapolis, Minnesota, United States
Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (PET) Study
- Conditions
- Interventions
- First Posted Date
- 2010-01-08
- Last Posted Date
- 2010-02-26
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 38
- Registration Number
- NCT01044992
- Locations
- 🇫🇷
University Hospital, Toulouse, France
Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)
- Conditions
- Interventions
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT00845000
Effect of Levodopa on Human Multifocal Electroretinogram
- First Posted Date
- 2008-12-22
- Last Posted Date
- 2008-12-22
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 20
- Registration Number
- NCT00812760
- Locations
- 🇦🇹
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
Carbidopa/Levodopa Combined With Behavioral Therapy for the Treatment of Cocaine Dependence
- Conditions
- Interventions
- First Posted Date
- 2008-07-11
- Last Posted Date
- 2018-04-23
- Target Recruit Count
- 85
- Registration Number
- NCT00713583
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
A Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLS
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2008-10-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 361
- Registration Number
- NCT00625547
- Locations
- 🇨🇭
Pfizer Investigational Site, Zürich, Switzerland
Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 140
- Registration Number
- NCT00537017
Substance Abuse Pre-Treatment Screening Study
- First Posted Date
- 2007-02-22
- Last Posted Date
- 2023-12-20
- Target Recruit Count
- 7500
- Registration Number
- NCT00439049
- Locations
- 🇺🇸
University of Texas Medical School- Houston, Dept. of Psychiatry Mental Sciences Institute, Houston, Texas, United States
Dyskinesia in Parkinson's Disease (Study P04501)
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2018-11-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 253
- Registration Number
- NCT00406029
Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment
- Conditions
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2007-10-25
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 120
- Registration Number
- NCT00306124
- Locations
- 🇩🇪
University of Muenster, Department of Neurology, Muenster, North-Rhine Westphalia, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.